Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Parkland Health Center - Farmington — Farmington, Missouri
- Freeman Health System — Joplin, Missouri
- Sainte Genevieve County Memorial Hospital — Sainte Genevieve, Missouri
- Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
- Southeast Cancer Center — Cape Girardeau, Missouri
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Missouri: - Mosaic Life Care at Saint Joseph - Medical Center — Saint Joseph, Missouri
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Missouri: - Washington University in St. Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Missouri: - Washington University St. Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Sponsor: Duke University
NCT ID: NCT06069726
Sites in Missouri: - Saint Luke's Cancer Institute — Kansas City, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety…
Sponsor: Washington University School of Medicine
NCT ID: NCT06639607
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The stud…
Sponsor: Washington University School of Medicine
NCT ID: NCT07392957
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatmen…
Sponsor: Washington University School of Medicine
NCT ID: NCT07462507
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Missouri: - Saint Luke's Cancer Institute — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Industry
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Sponsor: Boston Scientific Corporation
NCT ID: NCT05303467
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03911388
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
EARLY Phase 1 Recruiting Academic/Other
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will…
Sponsor: Washington University School of Medicine
NCT ID: NCT06636162
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Academic/Other
This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is t…
Sponsor: Washington University School of Medicine
NCT ID: NCT05521984
Sites in Missouri: - Washington University School of Medicine/St. Louis Children's Hospital — St Louis, Missouri
EARLY Phase 1 Recruiting Academic/Other
Preclinical data have demonstrated the combination of azeliragon, a RAGE inhibitor, with radiation therapy (RT) can effectively reduce immune-suppressive myeloid cells and restore T-cell activation to improve tumor control in murine glioma…
Sponsor: Washington University School of Medicine
NCT ID: NCT06831526
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Missouri: - Massive Bio SYNERGY-AI site — Kansas City, Missouri
- Massive Bio SYNERGY-AI site — St Louis, Missouri